Inovio Pharmaceuticals, Inc.INONASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -5.87% |
| Q2 2025 | -11.97% |
| Q1 2025 | 24.88% |
| Q4 2024 | -31.22% |
| Q3 2024 | -18.87% |
| Q2 2024 | 10.41% |
| Q1 2024 | 21.22% |
| Q4 2023 | 11.29% |
| Q3 2023 | -34.71% |
| Q2 2023 | -21.32% |
| Q1 2023 | -28.36% |
| Q4 2022 | 27.30% |
| Q3 2022 | -41.40% |
| Q2 2022 | 0.87% |
| Q1 2022 | -39.35% |
| Q4 2021 | 96.01% |
| Q3 2021 | -33.50% |
| Q2 2021 | 81.35% |
| Q1 2021 | 48.44% |
| Q4 2020 | -0.58% |
| Q3 2020 | 18.23% |
| Q2 2020 | 17.09% |
| Q1 2020 | -13.15% |
| Q4 2019 | 14.98% |
| Q3 2019 | -14.89% |
| Q2 2019 | -7.80% |
| Q1 2019 | -7.49% |
| Q4 2018 | 20.66% |
| Q3 2018 | -2.72% |
| Q2 2018 | -8.61% |
| Q1 2018 | -0.26% |
| Q4 2017 | -3.41% |
| Q3 2017 | 6.83% |
| Q2 2017 | -2.70% |
| Q1 2017 | 2.64% |
| Q4 2016 | -11.37% |
| Q3 2016 | 37.44% |
| Q2 2016 | 7.93% |
| Q1 2016 | 16.58% |
| Q4 2015 | -2.94% |